Biovista and Solve ME/CFS Initiative achieve drug repositioning milestone with pre-IND meeting

May 30, 2013Press Releases

Charlottesville, VA and Charlotte, NC, May 29, 2013 /PRNewswire/- Biovista and Solve ME/CFS Initiative (formerly the CFIDS Association of America) announced today the successful completion of the first phase of their collaboration. Funded as part of  Solve ME/CFS Initiative’s Research Institute Without Walls, Biovista identified candidate treatments for CFS using its state-of-the-art COSS approach. Two candidate … Read More

Biovista President to present at the NYBA 2013 Annual Meeting

May 24, 2013Events

Biovista President Dr. Aris Persidis will be presenting at the New York Biotechnology Association 2013 Annual meeting. Dr Persidis will be presenting at the “Patient Perspectives: Seeking Cures, Not Just Returns” session and discuss Biovista’s work to date with Patient Advocacy Groups. According to the organizers “patient groups and disease foundations, no longer content to … Read More

GEN: Seasoned Drugs Offer Therapeutic Gold Mine

May 23, 2013Media coverage

Article by Caitlin Smith GEN: Genetic Engineering & Biotechnology, May 15, 2013 … Biovista has already repositioned two drugs for the progressive form of multiple sclerosis (MS), which has had few treatment options. Most MS drugs, for treatment of the relapsing-remitting form of MS, compromise the patients’ immune systems and have significant side effects. Biovista … Read More